Oruka Therapeutics (NASDAQ:ORKA) Lowered to “Sell” Rating by Wall Street Zen

Oruka Therapeutics (NASDAQ:ORKA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus increased their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. HC Wainwright reissued a “buy” rating on shares of Oruka Therapeutics in a research note on Wednesday, June 3rd. Barclays increased their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research note on Monday, April 27th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $131.30.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $69.89 on Friday. The firm has a 50 day simple moving average of $63.40 and a 200-day simple moving average of $43.94. Oruka Therapeutics has a 1-year low of $10.77 and a 1-year high of $91.00. The stock has a market cap of $4.22 billion, a price-to-earnings ratio of -36.03 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. Equities analysts expect that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the transaction, the senior vice president owned 16,406 shares of the company’s stock, valued at approximately $969,102.42. This trade represents a 38.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the transaction, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 174,055 shares of company stock worth $10,550,083. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ORKA. Goldman Sachs Group Inc. acquired a new stake in shares of Oruka Therapeutics in the 1st quarter valued at $2,505,000. JPMorgan Chase & Co. raised its holdings in shares of Oruka Therapeutics by 567.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at $28,000. Rhumbline Advisers acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at $320,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at $96,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.